高级检索
当前位置: 首页 > 详情页

A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [2]MolecularCell Laboratory for Kidney Disease, Shanghai, China [3]Shanghai Peritoneal Dialysis Research Center, Shanghai, China [4]UremiaDiagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China [5]Department ofNephrology, Shanghai Songjiang District Central Hospital, Shanghai, China [6]Department of Nephrology, Longhua Hospital,Shanghai University of Traditional Chinese Medicine, Shanghai, China [7]Department of Nephrology, Affiliated Hospital ofJiangxi University of Traditional Chinese Medicine, Nanchang China [8]Department of Nephrology, Central Hospital of ShanghaiJiading District, Shanghai, China [9]Department of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong UniversitySchool of Medicine, Shanghai, China [10]Department of Nephrology, Sixth People’s Hospital Affiliated to Shanghai Jiao TongUniversity School of Medicine, Shanghai, China [11]Department of Nephrology, Xinhua Hospital, Shanghai Jiao Tong UniversitySchool of Medicine, Shanghai, China [12]Department of Nephrology, Changhai Hospital, Naval Medical University, Shanghai,China [13]Department of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [14]Department of Nephrology, Shanghai Punan Hospital, Shanghai, China
出处:
ISSN:

关键词: automated peritoneal dialysis end-stage renal disease hemodialysis urgent-start peritoneal dialysis

摘要:
Introduction: Peritoneal dialysis (PD) shows promise for urgent-start dialysis in end-stage renal disease (ESRD), with automated PD (APD) having advantages. However, there is limited multicenter randomized controlled trial (RCT) evidence comparing APD with temporary hemodialysis (HD) for this indication in China. Methods: This multicenter RCT enrolled 116 patients with ESRD requiring urgent dialysis from 11 hospitals, randomized to APD or HD. Patients underwent a 2-week treatment with APD or HD via a temporary central venous catheter (CVC), followed by a maintenance PD. Outcomes were assessed over 12 months during 8 visits. The primary outcome was dialysis-related complications. Results: The 1-year incidence of dialysis-related complications was significantly lower in the APD group than in the HD group (25.9% vs. 56.9%, P = 0.001). No significant differences were found between the groups in terms of PD catheter survival rates (P P = 0.388), peritonitis-free survival rates (P P = 0.335), and patient survival rates (P P = 0.329). In terms of health economics, the total direct medical cost of the initial hospitalization for patients with ESRD was significantly lower in the APD group (27,008.39 CNY) than in the HD group (42,597.54 CNY) (P P = 0.001), whereas the duration of the first hospital stay showed no significant difference (P P = 0.424). Conclusion: For patients with ESRD needing urgent initiation of dialysis, APD was associated with a lower incidence of dialysis-related complications and lower initial hospitalization costs compared with HD, with no significant differences in PD catheter survival rate, peritonitis-free survival rates, or patient survival rates. These findings can guide clinical decision-making for the optimal dialysis modality for patients requiring urgent dialysis initiation.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 泌尿学与肾脏学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 泌尿学与肾脏学
JCR分区:
出版当年[2022]版:
Q1 UROLOGY & NEPHROLOGY
最新[2023]版:
Q1 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [2]MolecularCell Laboratory for Kidney Disease, Shanghai, China [3]Shanghai Peritoneal Dialysis Research Center, Shanghai, China [4]UremiaDiagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China [2]MolecularCell Laboratory for Kidney Disease, Shanghai, China [3]Shanghai Peritoneal Dialysis Research Center, Shanghai, China [4]UremiaDiagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China [*1]Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Shanghai 200127, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)